Interestingly, AIM2 gene was positively associated with the therapeutic efficacy of Brodalumab and negatively associated with Ustekinumab treatment response (Gong and Wang, 2021), which provide novel clues for clinical decisions on treatment for psoriasis. This evidence concerns the gene AIM2 and psoriasis.